Free Eye Drops Distribution To Mitigate Drug Side Effects Cleared By HHS OIG
Executive Summary
Program relies on a third-party vendor managing a Risk Evaluation and Mitigation Strategy associated with the drug to facilitate delivery of eye drops to patients.
You may also be interested in...
Long-Acting Antipsychotic Sampling Program In Hospitals Cleared By OIG Advisory Opinion
Sample program focuses only on inpatient use and in hospitals that do not accept Prescription Drug Marketing Act-compliant trial units. By improving adherence, program could lower federal health care costs over time, Office of Inspector General suggests.
Novartis CAR-T Patient Assistance Program Could Set Template For Other One-Time Treatments
HHS gives kickback exemption for program to provide Kymriah for free to certain eligible patients regardless of insurance provider. Treatment’s one-time use as a last resort therapy were key to the US government’s advisory opinion reasoning.
GSK’s Blenrep Wins BCMA Race, Carries Ocular Toxicity Warning
US FDA-approved belantamab mafodotin is indicated for heavily pre-treated multiple myeloma and has a list price of $23,900 per month. Its REMS could limit initial uptake, but response rates have been encouraging.